首页> 外文期刊>World Journal of Surgery: Official Journal of the Societe Internationale de Chirurgie, Collegium Internationale Chirurgiae Digestivae, and of the International Association of Endocrine Surgeons >Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.
【24h】

Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

机译:术前中性粒细胞与淋巴细胞之比(NLR)与胰腺腺癌根治性切除后无病生存期降低有关。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Serological proinflammatory markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been associated with reduced survival for many different types of cancer. This study determined the prognostic value of the preoperative value of these markers in patients with resectable pancreatic adenocarcinoma. METHODS: Consecutive patients who underwent pancreaticoduodenectomy for pancreatic ductal adenocarcinoma were entered into our database from 2001 to the present day. CRP, NLR, and PLR at the time of presentation were recorded as well as overall and disease-free survival. RESULTS: Seventy-four patients were identified. Overall median survival was 35.0 months and median disease-free survival was 27.0 months. Follow-up ranged from 1 to 125.8 months. Preoperative NLR was significantly greater in those patients who developed recurrence in the follow-up period (4.5 vs. 3.1). CRP and PLR were not found to differ significantly between the two groups. Kaplan-Meier survival analysis of patients with NLR > 5 demonstrated a disease-free survival of 12 months compared with 52 months for those patients with NLR < 5 (p < 0.001). CONCLUSION: Preoperative NLR offers important prognostic information regarding disease-free survival following curative resection of pancreatic ductal adenocarcinoma.
机译:背景:血清促炎性标志物,例如C反应蛋白(CRP),嗜中性白细胞与淋巴细胞之比(NLR)和血小板与淋巴细胞之比(PLR)与许多不同类型癌症的存活率降低相关。这项研究确定了这些标志物在可切除的胰腺腺癌患者中的术前价值。方法:从2001年至今,将接受胰十二指肠切除术治疗胰腺导管腺癌的连续患者输入我们的数据库。出现时记录CRP,NLR和PLR以及总体生存率和无病生存期。结果:确定了74例患者。总体中位生存期为35.0个月,平均无病生存期为27.0个月。随访时间为1到125.8个月。在随访期内复发的患者术前NLR明显更高(4.5 vs. 3.1)。两组之间的CRP和PLR没有明显差异。 NLR> 5的患者的Kaplan-Meier生存分析表明,无病生存期为12个月,而NLR <5的患者为52个月(p <0.001)。结论:术前NLR为胰腺导管腺癌根治性切除术后无病生存提供重要的预后信息。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号